Open AccessEffect of Oral Administration of Butyrivibrio fibrisolvens MDT-1 on Experimental Enterocolitis in Mice
Author(s) -
Sou Ohkawara,
Hideki Furuya,
Kousuke Nagashima,
Narito Asanuma,
Tsuneo Hino
Publication year - 2006
Publication title -
clinical and vaccine immunology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.649
H-Index - 77
eISSN - 1556-6811
pISSN - 1556-679X
DOI - 10.1128/cvi.00267-06
Subject(s) - cecum , enterocolitis , microbiology and biotechnology , probiotic , colitis , diarrhea , bloody diarrhea , oral administration , myeloperoxidase , inflammatory bowel disease , medicine , campylobacter jejuni , gastroenterology , biology , inflammation , bacteria , genetics , disease
Butyrivibrio fibrisolvens MDT-1, a butyrate-producing strain, was evaluated for use as a probiotic to prevent enterocolitis. Oral administration of the MDT-1 strain (109 CFU/dose) alleviated the symptoms of colitis (including body weight loss, diarrhea, bloody stool, organic disorder, and mucosal damage) that are induced in mice drinking water that contains 3.0% dextran sulfate sodium. In addition, myeloperoxidase (MPO) activity levels in colonic tissue were reduced, suggesting that MDT-1 mitigates bowel inflammation. The addition of MDT-1 culture supernatant inhibited the growth of nine clinical isolates ofCampylobacter jejuni andCampylobacter coli that could potentially cause enterocolitis. Infection of mice withC. coli 11580-3, one of the isolates inhibited by MDT-1 in vitro, resulted in diarrhea, mucosal damage, increased MPO activity levels in colonic tissue, increased numbers ofC. coli in the cecum, and decreased body weight gain. However, administration of MDT-1 to mice, prior to and duringC. coli infection, reduced these effects. These results suggest thatCampylobacter -induced enterocolitis can be alleviated by usingB. fibrisolvens as a probiotic.